Outcome MeasureWell-being

LOT-R

Life Orientation Test – Revised

2 Papers in Blossom

Papers Using LOT-R

Paywallindividual

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial

This secondary analysis of an RCT comparing psilocybin therapy to escitalopram in MDD patients (n=59) found that psilocybin produced superior improvements in cognitive biases. Psilocybin significantly increased self-reported optimism (d=1.1) and optimistic beliefs about desirable life events (d=1.1), while improving all three domains of dysfunctional attitudes (achievement, dependency, and self-control). Escitalopram showed more modest effects, reducing pessimism about negative events and improving only the achievement domain of dysfunctional attitudes.

Published
Journal
European Neuropsychopharmacology
Authors
Henry, J., Giribaldi, B., Nutt, D. J., Erritzoe, D., Carhart-Harris, R., Lyons, T.
Open Accessindividual

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

In a randomized, double‑blind, crossover trial of 51 patients with life‑threatening cancer, a single high dose of psilocybin produced large, rapid and sustained reductions in clinician- and self-rated depression and anxiety and increased quality of life, meaning and optimism, with about 80% of participants showing clinically significant improvement at six months. The therapeutic effects were mediated by the intensity of mystical‑type experiences during the session and were corroborated by community observer ratings.

Published
Journal
Journal of Psychopharmacology
Authors
Griffiths, R. R., Johnson, M. W.

Quick Facts

Full Name
Life Orientation Test – Revised
Domain
Well-being
Papers Indexed
2
Score Range
0–24
Interpretation
Higher = better
Unit
points
All Measures